NeuVasQ Biotechnologies’ €20 Million Series A Investment Round

Strelia advised Newton Biocapital on the deal.

Newton Biocapital acted as lead investor in the 20 million series A investment round in NeuVasQ Biotechnologies, a spin-off of the ULB active in the fight against neurological disorders.

Newton Biocapital is a life sciences investment fund active in Europe and Japan and NeuVasQ Biotechnologies is a spin-off of the ULB specialized in the development of novel therapies for brain disorders.

Newton Biocapital acted as lead investor and was joined by public and private investment partners for this successful series A round.

Strelia’s Corporate team was led by Laurent Verhavert (Picture) and Julie Lo Bue.

Involved fees earner: Julie Lo Bue – Strelia; Laurent Verhavert – Strelia;

Law Firms: Strelia;

Clients: Newton Biocapital;

Federica Tiefenthaler

Author: Federica Tiefenthaler